Can analysts adopt a bullish outlook for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)?

July 13, 2018 - By Eula Gilbert

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) LogoInvestors sentiment decreased to 1 in Q1 2018. Its down 0.03, from 1.03 in 2017Q4. It dropped, as 43 investors sold Alexion Pharmaceuticals, Inc. shares while 184 reduced holdings. 60 funds opened positions while 167 raised stakes. 200.94 million shares or 1.68% less from 204.38 million shares in 2017Q4 were reported.
Tiaa Cref Inv Management Lc holds 0.26% or 3.51 million shares in its portfolio. Amp Capital Invsts has 83,528 shares for 0.05% of their portfolio. Premier Asset Mgmt Llc owns 0.49% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 19,650 shares. Northern Capital Mngmt Limited Liability Com, Wisconsin-based fund reported 7,145 shares. Arizona State Retirement Systems has 0.06% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 55,004 shares. Zeke Capital Advsr Lc holds 0.06% or 5,661 shares in its portfolio. Qs Lc holds 21,410 shares. Oregon Pub Employees Retirement Fund stated it has 23,800 shares or 0.04% of all its holdings. Ubs Asset Mngmt Americas reported 1.88M shares stake. Rhumbline Advisers has 0.09% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 395,321 shares. Trexquant Invest Lp holds 0.35% or 44,818 shares in its portfolio. Highland Ltd Partnership reported 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 3.27M were reported by Orbimed Advsr Lc. Jefferies Gru Limited Liability Company holds 7,986 shares or 0% of its portfolio. Walleye Trading Ltd holds 0.01% or 22,493 shares.

Since February 5, 2018, it had 1 insider buy, and 15 insider sales for $3.94 million activity. Franchini Indrani Lall sold $169,696 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, February 6. 10,000 shares were bought by COUGHLIN CHRISTOPHER J, worth $1.21M. 3,363 shares were sold by Moriarty John B, worth $389,099 on Tuesday, February 6. The insider Wagner Heidi L sold $76,805. $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Clancy Paul J. 1,862 shares were sold by LAW ANNE-MARIE, worth $220,703.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 14 analysts covering Alexion Pharmaceuticals (NASDAQ:ALXN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Alexion Pharmaceuticals had 22 analyst reports since January 18, 2018 according to SRatingsIntel. The stock has “Buy” rating by Evercore on Tuesday, May 8. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by BMO Capital Markets on Thursday, February 8. The company was maintained on Friday, February 9 by Leerink Swann. The firm has “Buy” rating given on Thursday, March 15 by Robert W. Baird. Deutsche Bank maintained it with “Buy” rating and $161 target in Friday, February 9 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by Credit Suisse on Tuesday, June 5. On Tuesday, May 8 the stock rating was maintained by Piper Jaffray with “Buy”. On Friday, April 27 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Thursday, January 18, the company rating was reinitiated by Credit Suisse. The firm has “Buy” rating given on Monday, March 19 by Nomura. Below is a list of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) latest ratings and price target changes.

05/06/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $149 New Target: $154 Maintain
08/05/2018 Broker: Piper Jaffray Rating: Buy New Target: $170.0000 Maintain
08/05/2018 Broker: Evercore Rating: Buy New Target: $150.0000 Maintain
30/04/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $170 New Target: $173 Maintain
27/04/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $151 New Target: $155 Maintain
23/04/2018 Broker: Raymond James Rating: Buy Maintain
20/04/2018 Broker: Evercore Rating: Buy
19/03/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $148 New Target: $156 Maintain
16/03/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $147 New Target: $149 Maintain
15/03/2018 Broker: Robert W. Baird Rating: Buy New Target: $160.0 Maintain

The stock increased 1.02% or $1.37 during the last trading session, reaching $135.66. About 920,614 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 19.53% since July 13, 2017 and is uptrending. It has outperformed by 6.96% the S&P500.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $30.18 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 58.35 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

More recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Nasdaq.com which released: “3 Big Stock Charts for Thursday: Express Scripts Holding Co, Alexion Pharmaceuticals and Ventas” on July 05, 2018. Also Bizjournals.com published the news titled: “Future home of PTC, Alexion could sell for $450M” on June 20, 2018. 247Wallst.com‘s news article titled: “Short Sellers Back Off Major Biotechs” with publication date: July 12, 2018 was also an interesting one.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.